INLEXZO gemcitabine intravesical system

Drug Class

Intravesical drug delivery system

Mechanism

Maintains sustained release of gemcitabine directly into the bladder, which is subsequently converted to active metabolites that disrupt DNA synthesis.

Approved Indication

BCG-unresponsive, non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors, per its FDA approval.

What This Means For Patients

Inlexzo is a novel drug-delivery system that is inserted into the bladder to release gemcitabine chemotherapy continuously over several weeks. It is used for patients with high-risk, BCG-unresponsive bladder cancer, and is accessible in Hainan Boao Lecheng.

Regulatory Approvals

• FDA — approved (2025) — source

Pivotal Clinical Evidence

• SunRISe-1 — Daneshmand et al., J Clin Oncol 2025 (NCT04640623) — DOI

Sources

• https://www.jnj.com/media-center/press-releases/johson-and-johnson-announces-fda-approval-of-inlexzo-for-bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer
• https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218204